Please login to the form below

Not currently logged in
Email:
Password:

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

UK trumpets life sciences post-Brexit ‘sector deal’

UK trumpets life sciences post-Brexit ‘sector deal’

with the European Bioinformatics Institute, the Wellcome Trust Sanger Institute, Biogen and Takeda that makes genetic and biological data freely available to researchers.

Latest news

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    The South Korea-based joint venture between Samsung and Biogen says the new biosimilar, called Ontruzant, has been approved for the full range of registered indications for Herceptin (trastuzumab), including early

  • New data could unlock bigger market for Roche’s Hemlibra New data could unlock bigger market for Roche’s Hemlibra

    Haemophilia A treatment is being transformed by a series of long-acting Factor VIII products such as Biogen’s Eloctate, Shire’s Adynovate, Bayer’s Kovaltry and CSLBehring’s Afstyla, which

  • Sanofi licences Principia MS drug in $805m deal Sanofi licences Principia MS drug in $805m deal

    Sanofi ‘s established oral MS therapy is Aubagio (teriflunomide), which got off to a slow start after its launch in 2012 in the face of competition from rival drugs from Biogen ... With a 27% growth it is still one of Sanofi’s most important products,

  • Life lessons Life lessons

    That’s what explains the rise of companies like Roche, Gilead and Biogen and the relative struggles of Pfizer and GSK, among others.

  • Biogen says trial extension data keep Alzheimer's drug on track Biogen says trial extension data keep Alzheimer's drug on track

    Biogen says trial extension data keep Alzheimer's drug on track. Releases updated results from the PRIME trial of anti-amyloid drug aducanumab. ... Biogen has continued to drip feed positive data on its Alzheimer's candidate aducanumab, and now says a

More from news
Approximately 85 fully matching, plus 252 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2017

    Two pre phase 2 molecules to treat neuro-degenerative disease have been licensed to Biogen and Roche for a combined $1.085bn. ... BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for  progressive supranuclear palsy.

  • Managing medication non-adherence Managing medication non-adherence

    efficacious. Biogen has been playing in this space for a few years now and conducted a clinical trial with PatientsLikeMe that showed how people living with multiple sclerosis (MS) can use

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Biogen has begun enrolment in two phase III trials of aducanumab but those results are not likely before 2020. ... Leading the pack are Merck &Co’s verubecestat, pivotal data on which is due in mid-2017, Lilly and AstraZeneca’s LY3314814 and

  • Deal Watch January 2017 Deal Watch January 2017

    In a similar vein, Forward Pharma and Biogen also reached a settlement agreement over the Tecfidera patent dispute by closing an irrevocable licence valued at $1.25bn. ... Biogen. Patent settlement. Tecfidera (dimethyl fumarate). 1, 250. Merrimack

More from intelligence
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 14 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....
Grabbing your audience*
Highlighting one of our recent pieces of work - a powerful disease awareness film created in partnership with Watchable Films...

Infographics